ONCY.US Oncolytics Biotech Inc

Healthcare Biotechnology USA Stocks
0.3399 USD
Close of Nov 16, 2026
0.3363 1.30
Market cap
USD 44.6M
P/E
-
P/B
1,055.04x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is ONCY.US undervalued?

Graham number

The Graham number of Oncolytics Biotech Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Oncolytics Biotech Inc fundamental analysis

No fundamental analysis for Oncolytics Biotech Inc yet.

Oncolytics Biotech Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Oncolytics Biotech Inc

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal ("GI") tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in i…

Full company profile